Massalia Therapeutics secures seed financing to develop its SANF factor for treating cancer and fibrosis. The company aims to begin first-in-man trials within six months.

Massalia Therapeutics has initiated its seed financing to develop the SANF factor, targeting conditions related to fibrosis and neoplasia. The company's preclinical program is ready for an Investigational New Drug application, intending to start human trials soon. The average cost for study registration and early testing is projected between €0.5m and €5m. The support from Landmark BioVentures and Aix-Marseille University has been crucial for the company's foundation.